ACA
DSGN icon

Avoro Capital Advisors’s Design Therapeutics DSGN Stock Holding History

Avoro Capital Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,500,000
Closed -$22.1M – 47
2023
Q2 		$22.1M Hold
3,500,000
– – 0.3% 31
2023
Q1 		$20.2M Buy
3,500,000
+1,227,778
+54% +$9.18M 0.3% 31
2022
Q4 		$23.3M Buy
2,272,222
+50,000
+2% +$678K 0.35% 31
2022
Q3 		$37.2M Hold
2,222,222
– – 0.69% 23
2022
Q2 		$31.1M Hold
2,222,222
– – 0.61% 26
2022
Q1 		$35.9M Buy
2,222,222
+586,122
+36% +$8.98M 0.66% 23
2021
Q4 		$35M Buy
1,636,100
+167,782
+11% +$2.88M 0.6% 26
2021
Q3 		$21.6M Hold
1,468,318
– – 0.34% 38
2021
Q2 		$26.4M Hold
1,468,318
– – 0.46% 33
2021
Q1 		$39.7M Buy
+1,468,318
New +$49.5M 0.69% 30

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avoro Capital Advisors's DSGN Position: Q3 2023 in Review

Avoro Capital Advisors sold out of Design Therapeutics (DSGN) in Q3 2023, closing a stake of 3,500,000 shares — an estimated $22.1M sold.

Avoro Capital Advisors first reported a position in DSGN in Q1 2021 and held it in 10 quarters. The position peaked at $39.7M in Q1 2021. 87 funds tracked by Wall St. Rank hold DSGN as of Q3 2023.

  • Avoro Capital Advisors reported no remaining Design Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Avoro Capital Advisors sold 3,500,000 Design Therapeutics shares in Q3 2023, an estimated $22.1M.
  • Avoro Capital Advisors first reported a position in Design Therapeutics in Q1 2021 and held it in 10 quarters.
  • Avoro Capital Advisors's Design Therapeutics position peaked at $39.7M in Q1 2021.
  • 87 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2023.

Based on Avoro Capital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.